Home » Newsletters » BioWorld

BioWorld

Dec. 23, 1992

View Archived Issues

GENZYME GRANTED TWO PATENTS

SCICLONE RESTRUCTURES SINGAPORE VENTURE

PIGS POTENTIAL HUMAN ORGAN DONORS

APBI EARNINGS LOWER THAN EXPECTED

PROCYTE PACT WITH KAKEN

CONSORTIUM GETS MATCHING GRANT

BIO-INTERFACES SELLS LIFECORE SHARES

CAMBRIDGE BIOTECH LICENSES TB TEST TECHNOLOGY

VESTAR TO CO-DEVELOP RADIOTHERAPY

STEM CELL TECHNOLOGY VS. CANCER

THERATECH UNDERWRITERS EXERCISE OPTION

AMERICAN BIOGENETIC LICENSING PACT

BIOMERICA DEVELOPS ELISA TEST

CURATIVE GETS PATENT

BIOJECT BECOMES SUBSIDIARY

COLLABORATIVE GETS SBIR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...